-
H.C. Wainwright Assumes Aura Biosciences (AURA) at Buy
-
Citizens JMP Reiterates Market Outperform Rating on Aura Biosciences (AURA)
-
Citizens JMP Reiterates Market Outperform Rating on Aura Biosciences (AURA)
-
Aura Biosciences, Inc. (AURA) Misses Q1 EPS by 7c
-
Aura Biosciences (AURA) Prices Share Offering at $4.90/sh
-
Aura Biosciences (AURA) Announces Proposed Share and Warrant Offering
-
Citizens JMP Reiterates Market Outperform Rating on Aura Biosciences (AURA)
-
Aura Biosciences (AURA) Announces Appointment of Teresa Bitetti to Board of Directors
-
Aura Biosciences (AURA) PT Lowered to $19 at Citizens JMP
-
Aura Biosciences (AURA) PT Raised to $25 at H.C. Wainwright
-
Aura Biosciences (AURA) Presents Positive Data from Phase 1 Trial of Bel-sar
-
H.C. Wainwright Reiterates Buy Rating on Aura Biosciences (AURA)
-
Aura Biosciences (AURA) Announces Additional Data from Ongoing Phase 1 Trial
-
Aura Biosciences, Inc. (AURA) Tops Q3 EPS by 2c
-
TD Cowen Reiterates Buy Rating on Aura Biosciences (AURA)
-
Aura Biosciences (AURA) PT Raised to $23 at Scotiabank
-
Aura Biosciences (AURA) PT Raised to $22 at H.C. Wainwright
-
Aura Biosciences (AURA) PT Raised to $24 at BTIG
-
Aura Biosciences (AURA): Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Ph
-
H.C. Wainwright Reiterates Buy Rating on Aura Biosciences (AURA)
-
TD Cowen Reiterates Buy Rating on Aura Biosciences (AURA)
-
Aura Biosciences (AURA) Reports Positive Phase 2 End of Study Results Evaluating Bel-sar
-
Aura Biosciences, Inc. (AURA) Tops Q2 EPS by 4c

